Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Date of authorisation: 08/01/2018, Revision: 25, Status: Authorised

Quarterly System Demo - Q4 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 December 2025, 09:30 (CET) to 16 December 2025, 12:35 (CET)

Overview of (invented) names reviewed in November 2025 by the Name Review Group (NRG) adopted at the CHMP meeting of 11 December 2025

Human medicines European public assessment report (EPAR): Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals), pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted), Date of authorisation: 10/10/2009, Revision: 12, Status: Authorised

EMA/PE/0000182345

EMA/PE/0000182333

EMA/PE/0000182297

Opinion/decision on a Paediatric investigation plan (PIP): Imcivree, setmelanotide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: EMA/PE/0000182239

Opinion/decision on a Paediatric investigation plan (PIP): Inaqovi, cedazuridine,decitabine, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Blood and lymphatic system disorders, PIP number: EMA/PE/0000182217

Opinion/decision on a Paediatric investigation plan (PIP): Stivarga, regorafenib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: EMA/PE/0000182170